Eli Lilly and Company stock at EUR 1,298.20, down 0.90%
Published on 11/13/2026 at 08:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBusiness and market context
- Eli Lilly researches, develops and commercializes human medicines worldwide.
- The portfolio spans diabetes, oncology, autoimmune and neurological treatments.
- The next market focus is the stock's ability to hold above the latest Xetra close.
Eli Lilly and Company stock traded at EUR 1,298.20 on Lang & Schwarz at 08:12 CET on Friday, November 13, 2026, 0.90 percent below the Xetra close of Thursday, November 12, 2026 at EUR 1,310.00.
Pharmaceutical portfolio remains broad
Eli Lilly is a global pharmaceutical company focused on the research, development and commercialization of human medicines. Its portfolio includes treatments for diabetes, cancer, autoimmune diseases, neurological conditions and other major therapeutic areas.
The premarket indication leaves the stock below the latest Xetra close. For investors, the key near-term signal is whether regular trading in Germany narrows or extends that gap rather than the indication itself establishing a lasting trend.
US equities set the broader backdrop for Eli Lilly stock through the S&P 500.
